Climb Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLYM research report →
Range $17 – $40
Price Chart
About the company
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody.
- CEO
- Aoife Brennan BCh MMSc
- IPO
- 2021
- Employees
- 28
- HQ
- Wellesley Hills, MA, US
Get TickerSpark's AI analysis on CLYM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $635.62M
- P/E
- -12.90
- PEG
- 0.64
- P/S
- 0.00
- P/B
- 3.40
- EV/EBITDA
- -9.61
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -31.79%
- ROIC
- -26.89%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-97,000+0.0%
- Op Income
- $-67,883,000
- Net Income
- $-59,851,000+19.0%
- EPS
- $-0.88+42.5%
- OCF Growth
- -249.3%
- FCF Growth
- -250.5%
- 52W High
- $18.33
- 52W Low
- $1.64
- 50D MA
- $13.93
- 200D MA
- $9.91
- Beta
- 0.07
- RSI (14)
- 35
- Avg Volume
- 1.37M
No earnings-call transcripts are available for CLYM yet.
- Free Float
- 85.9%
- Shares Outstanding
- 57.26M
- Float Shares
- 49.20M
Buy/sell ratio 0.80. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 135 ETFs
Biggest fund positions in CLYM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 28, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 40,000 |
| Sep 28, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 10,000 |
| Sep 28, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 10,000 |
| Sep 28, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 10,000 |
| Sep 28, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 40,000 |
| Sep 28, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 10,000 |
| Sep 28, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 10,000 |
| Sep 28, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 10,000 |
| Sep 15, 26 | Thomas Stephen Basil | sell | 100,000 |
| Jun 29, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 70,284 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CLYM coverage
Recent articles, reports, and earnings notes.
No research on CLYM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLYM report →Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval
seekingalpha.com · Oct 7
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
globenewswire.com · Oct 2
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
marketbeat.com · Sep 3
Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule
benzinga.com · Sep 3
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
globenewswire.com · Sep 3
Climb Bio to Present at Upcoming Investor Conferences
globenewswire.com · Sep 2
Climb Bio (NASDAQ:CLYM) Shares Up 10.9% Following Analyst Upgrade
defenseworld.net · Jul 28
Climb Bio (NASDAQ:CLYM) Sets New 52-Week High Following Analyst Upgrade
defenseworld.net · Jul 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.